Abiopharma

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

CorMedix to Participate in Upcoming Investor Conferences

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

New Form 6-K - Galmed Pharmaceuticals Ltd. Filed: 2025-08-28 AccNo: 0001493152-25-012420 Size: 2 MB

Dominari Holdings Files $2 Billion Shelf to Support Strategic Expansion

New Form 8-K - Imunon, Inc. Filed: 2025-08-28 AccNo: 0001493152-25-012417 Size: 235 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

LifeMD to Participate in Three Investor Conferences During September

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update